If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Inner ear barotrauma (IEBt), though much less common than MEBT, shares a similar external cause. Mechanical trauma to the inner ear can lead to varying degrees of conductive and sensorineural hearing loss as well as vertigo. It is also common for conditions affecting the inner ear to result in auditory hypersensitivity. Two possible mechanisms are associated with forced Valsalva manoeuvre. In the one, the Eustachian tube opens in response to the pressure, and a sudden rush of high pressure air into the middle ear causes stapes footplate dislocation and inward rupture of the oval or round window. In the other, the tube remains closed and increased cerebrospinal fluid pressure is transmitted through the cochlea and causes outward rupture of the round window. Inner ear barotrauma can be difficult to distinguish from Inner ear decompression sickness. Both conditions manifest as cochleovestibular symptoms. The similarity of symptoms makes differential diagnosis difficult, which can delay appropriate treatment or lead to inappropriate treatment. Nitrogen narcosis, oxygen toxicity, hypercarbia, and hypoxia can cause disturbances in balance or vertigo, but these appear to be central nervous system effects, not directly related to effects on the vestibular organs. High-pressure nervous syndrome during heliox compression is also a central nervous system dysfunction. Inner ear injuries with lasting effects are usually due to round window ruptures, often associated with Valsalva maneuver or inadequate middle ear equalisation.
Another benefit with surgical intervention is visualization and evacuation of any condral fragments or loose bodies that may increase arthritis risk, lead to decreased range of motion of the joint as well as pain. In some instances, primarily seen with femoral head fractures on the weight bearing surface of the bone, joint replacement is indicated. The femoral head is known for leading to avascular necrosis and ORIF is not sufficient to maintain the blood supply to the fractured fragment. Therefore, replacement of the femoral head with a hemiarthroplasty or total hip arthroplasty is indicated in this case.
The Southern Oscillation is the atmospheric component of ENSO. This component is an oscillation in surface air pressure between the tropical eastern and the western Pacific Ocean waters. The strength of the Southern Oscillation is measured by the Southern Oscillation Index (SOI). The SOI is computed from fluctuations in the surface air pressure difference between Tahiti (in the Pacific) and Darwin, Australia (on the Indian Ocean). El Niño episodes have negative SOI, meaning there is lower pressure over Tahiti and higher pressure in Darwin. La Niña episodes on the other hand have positive SOI, meaning there is higher pressure in Tahiti and lower in Darwin. Low atmospheric pressure tends to occur over warm water and high pressure occurs over cold water, in part because of deep convection over the warm water. El Niño episodes are defined as sustained warming of the central and eastern tropical Pacific Ocean, thus resulting in a decrease in the strength of the Pacific trade winds, and a reduction in rainfall over eastern and northern Australia. La Niña episodes are defined as sustained cooling of the central and eastern tropical Pacific Ocean, thus resulting in an increase in the strength of the Pacific trade winds, and the opposite effects in Australia when compared to El Niño. Although the Southern Oscillation Index has a long station record going back to the 1800s, its reliability is limited due to the latitudes of both Darwin and Tahiti being well south of the Equator, so that the surface air pressure at both locations is less directly related to ENSO.
This is based on the beta decay of rubidium-87 to strontium-87, with a half-life of 50 billion years. This scheme is used to date old igneous and metamorphic rocks, and has also been used to date lunar samples. Closure temperatures are so high that they are not a concern. Rubidium-strontium dating is not as precise as the uranium–lead method, with errors of 30 to 50 million years for a 3-billion-year-old sample. Application of in situ analysis (Laser-Ablation ICP-MS) within single mineral grains in faults have shown that the Rb-Sr method can be used to decipher episodes of fault movement.
== Function == This gene is a member of the transferrin receptor-like family and encodes a single-pass type II membrane protein with a protease associated (PA) domain, an M28 peptidase domain and a transferrin receptor-like dimerization domain. This protein mediates cellular uptake of transferrin-bound iron and mutations in this gene have been associated with hereditary hemochromatosis type III. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized.
Sources: en.wikipedia.org
=== Diet === People with autoimmune hyperthyroidism (such as in Graves' disease) should not eat foods high in iodine, such as edible seaweed and seafood. From a public health perspective, the general introduction of iodized salt in the United States in 1924 resulted in lower rates of disease and goiters, and improved the lives of children whose mothers would not have eaten enough iodine during pregnancy, which would have lowered the IQs of their children.
== Further reading == Mortison, JD; Sherman, DH (2010). "Frontiers and opportunities in chemoenzymatic synthesis". J Org Chem. 75 (21): 7041–51. doi:10.1021/jo101124n. PMC 2966535. PMID 20882949. Kim, Jinhyun; Lee, Sahng Ha; Tieves, Florian; Paul, Caroline E.; Hollmann, Frank; Park, Chan Beum (5 July 2019). "Nicotinamide adenine dinucleotide as a photocatalyst". Science Advances. 5 (7): eaax0501. doi:10.1126/sciadv.aax0501.
Under traditional terminology, the American kestrel is the smallest raptor in the Americas, though the South American spot-winged falconet is almost as small. The American kestrel is sexually dimorphic, although there is some overlap in plumage coloration between the sexes. The bird ranges from 22 to 31 cm (8.7 to 12.2 in) in length with a wingspan of 51–61 cm (20–24 in). The female kestrel is larger than the male, though less so than larger falcons, being typically about 10% to 15% larger within a subspecies. The more northern subspecies tend to larger sizes (northern hemisphere), with a large northern female being about twice the size of a small southern male. The male typically weighs 80–143 g (2.8–5.0 oz), and the female 86–165 g (3.0–5.8 oz). In standard measurements, the wing bone is 16–21 cm (6.3–8.3 in) long, the tail is 11–15 cm (4.3–5.9 in) and the tarsus is 3.2–4 cm (1.3–1.6 in). Physically, American kestrels are leaner and less muscular than larger falcons. The pectoral flight muscles of the American kestrel make up only about 12% of its body weight, as compared to about 20% for the strongest flying falcons such as the peregrine falcon. The wings are moderately long, fairly narrow, and taper to a point. Their less muscular body type is adapted to energy-conserving ambush hunting, rather than spending large amounts of energy-consuming time on the wing and getting into long tail-chases of bird prey. For their size, they have strong talons and beaks, and can swiftly dispatch prey.
A milkette (also referred to as dairy milker, creamette or creamers) is a single serving of milk (2%) or cream (10% and 18%) in 12 millilitres (0.42 imp fl oz; 0.41 US fl oz) or 15 millilitres (0.53 imp fl oz; 0.51 US fl oz) containers used for coffee and tea. The single cup of milk is stored in a sealed (foil cover) plastic cup of milk or cream with long shelf life but must be refrigerated.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.